Chronic Obstructive Pulmonary Disease and Risk of Mortality in Patients with Venous Thromboembolism—The Tromsø StudyFunding K.G. Jebsen TREC is supported by an independent grant from Stiftelsen Kristian Gerhard Jebsen.
03 June 2019
19 October 2019
30 December 2019 (online)
Background Previous studies have shown increased mortality in venous thromboembolism (VTE) patients with chronic obstructive pulmonary disease (COPD), but it is unknown to what extent the association is influenced by the severity of COPD and physical inactivity.
Objectives This article investigates whether COPD, and stages of COPD, influenced the risk of mortality after a first episode of VTE when physical inactivity was taken into account.
Methods Patients with a first lifetime VTE (n = 256) were recruited among individuals who participated and performed spirometry in the fifth (2001–2002) and sixth (2007–2008) surveys of the Tromsø Study (n = 9577). All-cause mortality was registered up to December 31, 2015.
Results There were 123 deaths during a median of 2.9 years of follow-up. The overall mortality rate was 11.9 (95% confidence interval [CI] 10.0–14.2) per 100 person-years. The risk of death was twofold higher in COPD patients compared with those with normal airflow (hazard ratio [HR] 2.00, 95% CI 1.30–3.08) after multivariable adjustment. The risk of death increased with the severity of COPD. VTE patients with COPD stage III/IV had a fivefold increased risk of death (HR 5.20, 95% CI 2.65–10.2) compared with those without COPD, and 50% of these patients died within 3.5 months after the incident VTE event. Adjustment for physical inactivity had minor effect on the risk estimates.
Conclusion VTE patients with COPD had increased risk of death, particularly patients with severe COPD. The detrimental effect of COPD on mortality in VTE patients was apparently explained by factors other than physical inactivity among patients with COPD.
Conception and design: J.B.H. Data collection: T.B., S.K.B., H.M., J.B.H. Statistical analyses: T.B., S.K.B., L.E. Draft of manuscript: T.B., J.B.H. Interpretation of results: T.B., L.E., W.M.M., E.B.B., H.M., S.K.B., J.B.H. Critical revision of the manuscript: L.E., W.M.M., E.B.B., H.M., S.K.B., J.B.H.
- 1 Pengo V, Lensing AW, Prins MH. , et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350 (22) 2257-2264
- 2 Kahn SR, Shrier I, Julian JA. , et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149 (10) 698-707
- 3 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
- 4 Cushman M, Tsai AW, White RH. , et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117 (01) 19-25
- 5 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
- 6 Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Braekkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 2017; 15 (02) 295-303
- 7 Casazza F, Becattini C, Bongarzoni A. , et al. Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thromb Res 2012; 130 (06) 847-852
- 8 Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012; 9 (01) e1001155
- 9 Toelle BG, Xuan W, Bird TE. , et al. Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung Disease (BOLD) study. Med J Aust 2013; 198 (03) 144-148
- 10 Areias V, Carreira S, Anciães M, Pinto P, Bárbara C. Co-morbidities in patients with gold stage 4 chronic obstructive pulmonary disease. Rev Port Pneumol 2014; 20 (01) 5-11
- 11 Gunen H, Hacievliyagil SS, Kosar F. , et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26 (02) 234-241
- 12 Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124 (02) 459-467
- 13 Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010; 25 (04) 253-260
- 14 Curkendall SM, DeLuise C, Jones JK. , et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (01) 63-70
- 15 Chen WJ, Lin CC, Lin CY. , et al. Pulmonary embolism in chronic obstructive pulmonary disease: a population-based cohort study. COPD 2014; 11 (04) 438-443
- 16 Børvik T, Brækkan SK, Enga K. , et al. COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J 2016; 47 (02) 473-481
- 17 Winter JH, Buckler PW, Bautista AP. , et al. Frequency of venous thrombosis in patients with an exacerbation of chronic obstructive lung disease. Thorax 1983; 38 (08) 605-608
- 18 Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010; 35 (06) 1243-1248
- 19 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159 (05) 445-453
- 20 Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with chronic obstructive pulmonary disease. Am J Med 2012; 125 (10) 1010-1018
- 21 Carson JL, Kelley MA, Duff A. , et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326 (19) 1240-1245
- 22 Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155 (10) 1031-1037
- 23 Vorrink SN, Kort HS, Troosters T, Lammers JW. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 33
- 24 Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 2006; 129 (03) 536-544
- 25 Arem H, Moore SC, Patel A. , et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med 2015; 175 (06) 959-967
- 26 Lear SA, Hu W, Rangarajan S. , et al. The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet 2017; 390 (10113): 2643-2654
- 27 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso Study. Int J Epidemiol 2012; 41 (04) 961-967
- 28 Braekkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Body height and risk of venous thromboembolism: the Tromsø Study. Am J Epidemiol 2010; 171 (10) 1109-1115
- 29 American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152 (03) 1107-1136
- 30 Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag Study. Eur Respir J 2001; 18 (05) 770-779
- 31 Melbye H, Joensen L, Risør MB, Halvorsen PA. Symptoms of respiratory tract infection and associated care-seeking in subjects with and without obstructive lung disease; the Tromsø Study: Tromsø 6. BMC Pulm Med 2012; 12: 51
- 32 Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract 2008; 62 (08) 1219-1236
- 33 Evensen LH, Isaksen T, Hindberg K, Braekkan SK, Hansen JB. Repeated assessments of physical activity and risk of incident venous thromboembolism. J Thromb Haemost 2018; 16 (11) 2208-2217
- 34 World Health Organization. Tobacco Smoke and Involuntary Smoking. Lyon: World Health Organization International Agency for Research on Cancer; 2004
- 35 Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet 2015; 385 (9971): 899-909
- 36 Blix K, Gran OV, Severinsen MT. , et al. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. J Thromb Haemost 2018; 16 (07) 1327-1335
- 37 Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013; 144 (04) 1163-1178
- 38 Rinde LB, Lind C, Småbrekke B. , et al. Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2016; 14 (06) 1183-1191
- 39 Rinde LB, Småbrekke B, Mathiesen EB. , et al. Ischemic stroke and risk of venous thromboembolism in the general population: the Tromsø Study. J Am Heart Assoc 2016; 5 (11) 5
- 40 Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28 (06) 1245-1257
- 41 Grimnes G, Isaksen T, Tichelaar YIGV, Brækkan SK, Hansen JB. Acute infection as a trigger for incident venous thromboembolism: results from a population-based case-crossover study. Res Pract Thromb Haemost 2017; 2 (01) 85-92
- 42 Sharafkhaneh A, Spiegelman AM, Main K, Tavakoli-Tabasi S, Lan C, Musher D. Mortality in patients admitted for concurrent COPD exacerbation and pneumonia. COPD 2017; 14 (01) 23-29
- 43 Bonaccio M, Di Castelnuovo A, Pounis G. , et al; Moli-sani Study Investigators. A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study. Haematologica 2016; 101 (11) 1434-1441
- 44 Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J 2009; 33 (02) 262-272
- 45 Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest 2005; 128 (03) 1836-1852
- 46 Elagizi A, Kachur S, Lavie CJ. , et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis 2018; 61 (02) 142-150